搜索优化
English
全部
搜索
图片
视频
地图
资讯
Copilot
更多
购物
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
最佳匹配
最新
资讯
腾讯网
16 小时
FDA再批准礼来阿尔茨海默病药物!
礼来(Eli Lilly and Company)今日宣布,美国FDA已批准Kisunla(donanemab)的标签更新,新增推荐的滴定给药方案。Kisunla为一款每月一次的靶向淀粉样蛋白疗法,适用于早期阿尔茨海默病(AD)患者,包括轻度认知障碍 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Birthright order blocked
Central Texas flash floods
Suffers serious injuries
Death ruled a homicide
Los Angeles joins ACLU suit
Sentenced to 8+ years
Hiker dies in Grand Canyon
Tunnel collapses in LA
Won't revive immigration law
Utah judge sets execution
US sanctions UN official
Ex-doctor refuses to answer
Six firefighters injured
Barbie with Type 1 diabetes
Russian strikes on Kyiv
Confirmed to lead FAA
Loan interest to restart
Bitcoin hits record high
Ex-Jazz coach, GM dies
Six agents suspended
Copper tariffs to start Aug 1
Is Outlook down?
Interim NASA administrator
Makes first visit to Asia
To release web browser
Cases hit highest level
Cyclist LeMond honored
Booker gets max extension
反馈